BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, June 15, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» Candid, Epimab ink $1B T-cell engager deal in autoimmune disease
To read the full story,
subscribe
or
sign in
.
Candid, Epimab ink $1B T-cell engager deal in autoimmune disease
Dec. 17, 2024
By
Tamra Sami
Candid Therapeutics Inc. and Epimab Biotherapeutics Inc. have entered a $1 billion research collaboration to discover and develop novel T-cell engager candidates for autoimmune indications.
BioWorld
BioWorld Asia
Deals and M&A
Inflammatory
Musculoskeletal
Cell therapy
Asia-Pacific
China
